FDA approval for Kynmobi for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease. Sunovion Pharma

-Sunovion Pharmaceuticals Inc. has announced that the FDA has approved Kynmobi (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re-emergence or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or other symptoms. These disruptive episodes can occur in the morning upon waking and throughout the day. Kynmobi dissolves under the tongue to help people with PD improve their OFF symptoms as needed. Sunovion expects Kynmobi to be available in U.S. pharmacies in September 2020.